Indivior PLC (LON:INDV – Get Free Report) shares dropped 16% during trading on Thursday . The company traded as low as GBX 548.71 ($6.90) and last traded at GBX 729.50 ($9.18). Approximately 78,684,203 shares changed hands during trading, an increase of 2,668% from the average daily volume of 2,842,694 shares. The stock had previously closed at GBX 868 ($10.92).
Analyst Ratings Changes
Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 1,800 ($22.65) price target on shares of Indivior in a research note on Tuesday, December 17th.
Check Out Our Latest Stock Report on Indivior
Indivior Stock Down 15.7 %
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- Most Volatile Stocks, What Investors Need to Know
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- EV Stocks and How to Profit from Them
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- What is a SEC Filing?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.